{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:45:48Z","timestamp":1790282748076,"version":"4.1.0"},"reference-count":97,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK081817"],"award-info":[{"award-number":["DK081817"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hepatitis C virus (HCV) infection often causes liver diseases, including fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Liver fibrosis is the outcome of the wound healing response to tissue damage caused by chronic HCV infection. This process is characterized by the excessive accumulation of extracellular matrix (ECM) proteins, such as collagen fibers secreted by activated hepatic stellate cells (HSCs). Activation of HSCs from the quiescent stage is mediated by different mechanisms, including pro-inflammatory cytokines and chemokines released from HCV-infected hepatocytes and liver macrophages. HCV infection modulates the expression of different microRNAs that can be transported and delivered to the HSCs via exosomes released from infected cells, also leading to the development of advanced disease pathogenesis. Although recent advancements in direct-acting antiviral (DAA) treatment can efficiently control viremia, there are very few treatment strategies available that can be effective at preventing pathogenesis in advanced liver fibrosis or cirrhosis in patients. Assessment of fibrosis is considered to be the major part of proper patient care and decision making in clinical practice. In this review, we highlighted the current knowledge of molecular mechanisms responsible for the progression of liver fibrosis in chronically HCV-infected patients, and currently available methods for evaluation of fibrosis in patients. A detailed understanding of these aspects at the molecular level may contribute to the development of new therapies targeting HCV-related liver fibrosis.<\/jats:p>","DOI":"10.3390\/cells8101249","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T12:14:05Z","timestamp":1571055245000},"page":"1249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis"],"prefix":"10.3390","volume":"8","author":[{"given":"Mousumi","family":"Khatun","sequence":"first","affiliation":[{"name":"Department of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-6292","authenticated-orcid":false,"given":"Ratna B.","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO 63104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.30214","article-title":"Hepatitis C virus manipulates humans as its favorite host for long term relationship","volume":"69","author":"Ray","year":"2018","journal-title":"Hepatology"},{"key":"ref_2","unstructured":"(2019, October 12). World Health Organization Fact Sheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/2050640619840149","article-title":"Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges","volume":"7","author":"Ekpanyapong","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of Hepatic Fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ncpgasthep0055","article-title":"Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications","volume":"1","author":"Friedman","year":"2004","journal-title":"Nat. Clin. Pr. Gastroenterol. Hepatol."},{"key":"ref_8","first-page":"100","article-title":"Mechanisms involved in liver damage resolution after hepatitis C virus clearance","volume":"19","year":"2017","journal-title":"Med. Univ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/13543784.2015.1057568","article-title":"Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis","volume":"24","author":"Jaroszewicz","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","article-title":"Evolving challenges in hepatic fibrosis","volume":"7","author":"Friedman","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000486812","article-title":"Risk of de novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals","volume":"7","author":"Finkelmeier","year":"2018","journal-title":"Liver Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5501\/wjv.v4.i1.33","article-title":"Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection","volume":"4","author":"Waheed","year":"2015","journal-title":"World J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/gast.2003.50018","article-title":"Progression of fibrosis in chronic hepatitis C","volume":"124","author":"Ghany","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dejan, B., Vuk, V., Suzana, P., Danijela, J., Slobodanka, M., Predrag, D., Dusko, A., Aleksandra, A., Dragic, B., and Jelena, C. (2019). Chronic hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221142"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1128\/JVI.01962-13","article-title":"Hepatitis C virus induces interleukin-1\u03b2 (IL-1\u03b2)\/IL-18 in circulatory and resident liver macrophages","volume":"87","author":"Shrivastava","year":"2013","journal-title":"J. Virol."},{"key":"ref_18","first-page":"9261","article-title":"Cytokinome profile evaluation in patients with hepatitis C virus infection","volume":"20","author":"Capone","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Negash, A.A., Ramos, H.J., Crochet, N., Lau, D.T., Doehle, B., Papic, N., Delker, D.A., Jo, J., Bertoletti, A., and Hagedorn, C.H. (2013). IL-1\u03b2 production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003330"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.it.2011.01.003","article-title":"Inflammasome activation and IL-1\u03b2 and IL-18 processing during infection","volume":"32","author":"Netea","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.gastro.2005.03.089","article-title":"Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells","volume":"129","author":"Preimel","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.29170","article-title":"Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells","volume":"66","author":"Sasaki","year":"2017","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/hep.29346","article-title":"Hepatitis c virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model","volume":"66","author":"Sasaki","year":"2017","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3389\/fimmu.2018.02201","article-title":"Inflammasome: A double-edged sword in liver diseases","volume":"9","author":"Luan","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/infdis\/jis926","article-title":"Pathogenesis of accelerated fibrosis in HIV\/HCV co-infection","volume":"207","author":"Lin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1053\/j.gastro.2010.03.008","article-title":"HCV regulates TGF-\u03b21 production through the generation of reactive oxygen species in an NF\u03baB-dependent manner","volume":"138","author":"Lin","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1074\/jbc.M110.168286","article-title":"HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF\u0138B","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.26296","article-title":"Upregulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression","volume":"58","author":"Shrivastava","year":"2013","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/hep.28660","article-title":"Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C","volume":"64","author":"Matsuura","year":"2016","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3748\/wjg.v22.i4.1487","article-title":"MicroRNA-mediated interactions between host and hepatitis C virus","volume":"22","author":"Li","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11549","DOI":"10.1038\/srep11549","article-title":"Integrative miRNA and gene expression profiling analysis of human quiescent hepatic stellate cells","volume":"5","author":"Coll","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18632\/oncotarget.6447","article-title":"MicroRNA-17-5p-activated Wnt\/beta-catenin pathway contributes to the progression of liver fibrosis","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tzur, G., Israel, A., Levy, A., Benjamin, H., Meiri, E., Shufaro, Y., Meir, K., Khvalevsky, E., Spector, Y., and Rojansky, N. (2009). Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007511"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"G101","DOI":"10.1152\/ajpgi.00220.2009","article-title":"Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation","volume":"298","author":"Venugopal","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.febslet.2009.01.034","article-title":"Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation","volume":"583","author":"Ji","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/infdis\/jir186","article-title":"Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture","volume":"203","author":"Bandyopadhyay","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1128\/JVI.03060-13","article-title":"Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis","volume":"88","author":"Sarma","year":"2014","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sarma, N.J., Tiriveedhi, V., and Subramanian, V. (2012). Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050826"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jvh.12696","article-title":"Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients","volume":"24","author":"Shaker","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virusres.2018.06.007","article-title":"miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients","volume":"253","author":"Zoheiry","year":"2018","journal-title":"Virus Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.3748\/wjg.v21.i25.7814","article-title":"miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan","volume":"21","author":"Werling","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4149\/av_2016_03_242","article-title":"The possible role of NS3 protease activity of hepatitis C virus on fibrogenesis and miR-122 expression in hepatic stellate cells","volume":"60","author":"Khanizadeh","year":"2016","journal-title":"Acta Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/jmv.24230","article-title":"MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection","volume":"87","author":"Lee","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/labinvest.2010.126","article-title":"Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans","volume":"90","author":"Marquez","year":"2010","journal-title":"Lab Invest."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00705-015-2474-3","article-title":"Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7","volume":"160","author":"Zhu","year":"2015","journal-title":"Arch. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramachandran, S., Ilias-Basha, H., and Sarma, N.J. (2013). Hepatitis C virus induced miR200c down modulates FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070744"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nature05874","article-title":"Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project","volume":"447","author":"Birney","year":"2007","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2009.02.006","article-title":"Evolution and functions of long noncoding RNAs","volume":"136","author":"Ponting","year":"2009","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3389\/fmicb.2017.01833","article-title":"Long non-coding RNAs in hepatitis C virus-infected cells","volume":"8","author":"Barriocanal","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41467-018-07956-7","article-title":"Expression of novel long noncoding RNAs defines virus-specific effector and memory CD8+ T cells","volume":"10","author":"Hudson","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccr.2014.03.010","article-title":"A long noncoding RNA activated by TGF-\u03b2 promotes the invasion-metastasis cascade in hepatocellular carcinoma","volume":"25","author":"Yuan","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2016.02.020","article-title":"Long non-coding RNA GAS5 inhibited hepatitis C virus replication by binding viral NS3 protein","volume":"492","author":"Qian","year":"2016","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Plissonnier, M.L., Herzog, K., Levrero, M., and Zeisel, M.B. (2018). Non-coding RNAs and hepatitis C virus-induced hepatocellular carcinoma. Viruses, 10.","DOI":"10.3390\/v10110591"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e01215","DOI":"10.1128\/JVI.01215-18","article-title":"Association between microRNA-373 and long noncoding RNA NORAD in hepatitis C virus-infected hepatocytes impairs Wee1 expression for growth promotion","volume":"92","author":"Sur","year":"2018","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2017.03.008","article-title":"LncRNA-ATB\/microRNA-200a\/\u03b2-catenin regulatory axis involved in the progression of HCV-related hepatic fibrosis","volume":"618","author":"Fu","year":"2017","journal-title":"Gene"},{"key":"ref_58","first-page":"29","article-title":"Role of lncRNA-activated by transforming growth factor beta in the progression of hepatitis C virus-related liver fibrosis","volume":"22","author":"Fu","year":"2016","journal-title":"Discov. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri855","article-title":"Exosomes: Composition, biogenesis and function","volume":"2","author":"Zitvogel","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15252\/embr.201439363","article-title":"Exosomes and other extracellular vesicles in host-pathogen interactions","volume":"16","author":"Schorey","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mam.2017.11.001","article-title":"Extracellular vesicles: Novel mediator for cell to cell communications in liver pathogenesis","volume":"60","author":"Devhare","year":"2018","journal-title":"Mol. Asp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13109","DOI":"10.1073\/pnas.1221899110","article-title":"Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells","volume":"110","author":"Ramakrishnaiah","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2014.10.040","article-title":"Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication","volume":"148","author":"Giugliano","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1128\/JVI.02383-15","article-title":"Knockdown of autophagy inhibits infectious hepatitis C virus release by the exosomal pathway","volume":"90","author":"Shrivastava","year":"2015","journal-title":"J. Virol."},{"key":"ref_65","first-page":"e02216","article-title":"Exosome-mediated intercellular communication between hepatitis C virus-infected hepatocytes and hepatic stellate cells","volume":"91","author":"Devhare","year":"2017","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12275-016-6240-3","article-title":"Hepatitis C virus infection stimulates transforming growth factor-\u03b21 expression through upregulating miR-192","volume":"54","author":"Kim","year":"2016","journal-title":"J. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.omtn.2019.01.006","article-title":"Exosomal transmission of microRNA from HCV replicating cells stimulates transdifferentiation in hepatic stellate cells","volume":"14","author":"Kim","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/apt.12820","article-title":"Review article: The efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar","volume":"40","author":"Karsdal","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Portal hypertension collaborative group","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2014.03.006","article-title":"Improving performance of liver biopsy in fibrosis assessment","volume":"61","author":"Asselah","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy","volume":"344","author":"Bravo","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Baranova, A., Lal, P., Birerdinc, A., and Younossi, Z.M. (2011). Non-invasive markers for hepatic fibrosis. BMC Gastroenterol., 11.","DOI":"10.1186\/1471-230X-11-91"},{"key":"ref_73","first-page":"986","article-title":"Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model","volume":"36","author":"Forns","year":"2002","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.163.2.218","article-title":"Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease","volume":"163","author":"Giannini","year":"2003","journal-title":"Arch. Int. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: A systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_78","first-page":"e10810","article-title":"Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: A pilot study","volume":"13","author":"Alboraie","year":"2013","journal-title":"Hepatol. Mon."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/hepr.12385","article-title":"Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns\u2019 index in chronic hepatitis C virus","volume":"45","author":"Alboraie","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","article-title":"Performance of transient elastography for the staging of liver fibrosis: A meta-analysis","volume":"134","author":"Ong","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1478-3231.2011.02660.x","article-title":"Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C","volume":"32","author":"Cardoso","year":"2012","journal-title":"Liver Int."},{"key":"ref_82","first-page":"2639248","article-title":"Pentraxin 3 detects clinically significant fibrosis in patients with chronic viral hepatitis C","volume":"2019","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.12395","article-title":"Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?","volume":"34","author":"Calvaruso","year":"2014","journal-title":"Liver Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of disease manifestations after HCV eradication","volume":"65","author":"Berenguer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa- 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.25696","article-title":"NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection","volume":"56","author":"Debes","year":"2012","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann. Int. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S637","DOI":"10.1016\/S0168-8278(15)31011-4","article-title":"Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir\/paritaprevir\/r, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis","volume":"62","author":"Wedemeyer","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0039-1685538","article-title":"Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: Critical review","volume":"39","author":"Fehily","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Bruno, S., Crosignani, A., Roffi, L., De Lisi, S., Rossi, S., Boccaccio, V., Zermiani, P., Mondelli, M., and Maisonneuve, P. (2014, January 9\u201313). SVR is associated with no risk reduction of HCC development in patients with HCV-related cirrhosis. A prospective, up to 23 years, cohort follow-up study. Proceedings of the EASL Meeting, London, UK.","DOI":"10.1016\/S0168-8278(14)60627-9"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ebiom.2019.07.043","article-title":"Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality","volume":"46","author":"Wang","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:26:08Z","timestamp":1760189168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/10\/1249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":97,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cells8101249"],"URL":"https:\/\/doi.org\/10.3390\/cells8101249","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]}}}